ű 哈尔滨誉衡药业股份有限公司 证券代码: 002437 证券简称: 誉衡药业 公告编号: 2023-054 哈尔滨誉衡药业股份有限公司 2023 年半年度报告 2023 年 7 月 29 日 第 1 页 哈尔滨誉衡药业股份有限公司 公司负责人胡晋、主管会计工作负责人纪作哲及会计机构负责人(会计主管人员)周小婧声明：保证本半年度报告中 财务报告的真实、准确、完整。 所有董事均已出席了审议本次半年报的董事会会议。 本公司风险因素详见"第三节 管理层讨论与分析—十、公司面临的风险和应对措施"。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 第 2 页 〖ç哈尔滨誉衡药业股份有限公司 | | | | 第一节 重要提示、目录和释义 … | | --- | | 第二节 公司简介和主要财务指标 . | | 一、公司简介 | | 二、联系人和联系方式 … | | 三、其他情况 | | 四、主要会计数据和财务指标 … | | 五、境内外会计准则下会计数据差异 … | | 六、非经常性损益项目及金额… | | 第三节 管理层讨论与分析 …………………………………………………………………………………………………………… ...

证券代码： 002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 | --- | --- | |------------------------|----------------------------| | | □ 分析师会议 | | 投资者关系活动类别 | 业绩说明会 路演活动 | | | （请文字说明其他活动内容） | | 参与单位名称及人员姓名 | 高级分析师黄静 | | 时间 | 下午 17:30~18:30 | | 地点 | 层会议室 | | 上市公司接待人 | | 员姓名经理王孟云 提出的问题及公司回复情况 1、出售持有的广州誉衡生物科技有限公司（以下简称"誉衡生 物"）的原因及未来公司是否会布局生物药领域 回复： 誉衡生物研发及销售投入较大，处于亏损状态，对公司业绩造成 较大影响：2023 年 1-5 月，公司已确认投资损失 3574 万元，预 计全年影响公司净利润的金额为-8,000 至-9,000 万元。 投资者关系活动 国内生物药行业竞争持续加剧，已有多款 PD-1/PD-L1 相关产品 主要内容介绍 获批上市，誉衡生物的赛帕利单抗注射液的优势不是很突出。 鉴 ...

| | □特定对象调研 □ 分析师会议 | | --- | --- | | 投资者关系活动 | □ 媒体采访 √ 业绩说明会 | | 类别 | □ 新闻发布会 □ 路演活动 | | | 现场参观 □ | | | 其他 （请文字说明其他活动内容） □ | | 参与单位名称及 | 投资者网上提问 | | 人员姓名 | | | 时间 | 年 月 日 2023 5 15 (周一) 下午 14:00~16:30 | | 地点 | 公司通过全景网"投资者关系互动平台"（https://ir.p5w.net）采 | | | 用网络远程的方式召开业绩说明会 | | 上市公司接待人 | 1、副总经理、董事会秘书刘月寅 | | 员姓名 | 2、董事、副总经理、财务总监纪作哲 投资者提出的问题及公司回复情况 | | | 公司就投资者在本次说明会中提出的问题进行了回复： 1、胡晋你好，你是誉衡董事长也是信邦制药董事，可以客 | | | 观评价一下两公司经营状况，市值管理和高管们的薪酬情况，深 | | | 交所的问询你们的理由也很充分，但作为对比是不是没可比性， | | | 你们高管对公司发展是否有信心，如有，是否可以用你们来之不 | ...

哈尔滨誉衡药业股份有限公司 证券代码：002437 证券简称：誉衡药业 公告编号：2023-039 哈尔滨誉衡药业股份有限公司 关于参加黑龙江辖区上市公司2023年投资者 网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 为进一步加强与投资者的互动交流，哈尔滨誉衡药业股份有限公司（以下简 称"公司"）将参加由黑龙江证监局、黑龙江省上市公司协会与深圳市全景网络 有限公司联合举办的"2023年黑龙江辖区上市公司投资者集体接待日活动"，现 将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）或关注微信公众号（名称：全景财经）或下载全景路演APP， 参与本次互动交流。 活动时间为2023年5月15日（周一）14:00-16:30。届时公司部分高管将在线 就公司2022年度业绩、公司治理、发展战略、经营状况、融资计划和可持续发展 等投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者踊跃参与！ 特此公告。 哈尔滨誉衡药业股份有限公司 董 事 会 二〇二三年五月十一日 第 ...

© 哈尔滨誉衡药业股份有限公司 证券代码: 002437 证券简称: 誉衡药业 公告编号: 2023-014 哈尔滨誉衡药业股份有限公司 2022 年年度报告 2023 年 4 月 第 1 页 哈尔滨誉衡药业股份有限公司 致股东 2022 年，是誉衡登陆资本市场的第十二个年头。 说到"十二"，总有循环、完整的感觉，比如一轮有十二个生肖，一年有十二个月，一天有十二个时辰。 于誉衡也是，在这十二年里，我们经历了前期的快速扩张，也经历了过去五年的收缩调整。所幸，在这 个轮回中，我们基本消化掉了过往沉淀的问题，比如，原控股股东的破产工作已经收尾、公司资产质量 不断改善、核心产品受医药政策冲击的负面影响已经见底。我们也在确保公司平稳运营、风险可控的前 提下，布局具有临床价值、差异化的产品，并不断完善 CMO 服务平台、提升营销服务能力。更重要的， 我们在这过程中积累了宝贵的经验和教训，变得更从容、更有韧性，更理性、也更有信心。 回望上市以来这十二年的风雨历程，万分感激广大股东给予我们的支持、批评和包容！ 2023 年，誉衡将进入一个全新的阶段。在这个阶段，我们不仅要把之前落下的功课补上，还要用较 长的一段时间，让誉衡重 ...

Financial Performance - The company's revenue for Q1 2023 was ¥681,168,970.96, a decrease of 12.02% compared to ¥774,211,987.48 in the same period last year[4] - Net profit attributable to shareholders reached ¥20,058,598.74, representing a significant increase of 1,909.35% from ¥998,263.43 year-on-year[4] - Basic and diluted earnings per share were both ¥0.0091, an increase of 1,720.00% compared to ¥0.0005 in the same period last year[4] - The total operating revenue for the current period is ¥681,168,970.96, a decrease of 11.99% compared to ¥774,211,987.48 in the previous period[20] - The net profit for the current period is ¥21,870,444.70, significantly higher than ¥3,046,070.09 in the previous period, marking a growth of 619.06%[21] - The total comprehensive income for the current period is ¥21,156,409.21, compared to ¥2,822,278.80 in the previous period, showing a substantial increase[21] Cash Flow - The net cash flow from operating activities was ¥83,699,367.15, up 47.30% from ¥56,821,196.52 in the previous year[4] - The net cash flow from operating activities was ¥83,699,367.15, an increase from ¥56,821,196.52 in the previous period, indicating a positive trend in operational cash generation[24] - The net cash flow from investing activities was ¥25,147,232.08, a turnaround from a negative cash flow of ¥117,006,134.10 in the previous year[9] - The net cash flow from financing activities was -¥101,258,939.96, compared to -¥27,724,573.13 in the previous period, showing increased cash outflows related to financing[25] - The total cash inflow from investment activities was ¥57,198,472.28, significantly lower than ¥314,461,007.58 in the previous period, reflecting a decrease in investment returns[24] - The net increase in cash and cash equivalents was ¥6,815,714.09, contrasting with a decrease of ¥88,440,630.07 in the previous period, suggesting improved liquidity management[25] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,948,401,721.10, a decrease of 3.09% from ¥4,074,185,955.01 at the end of the previous year[4] - The total liabilities amount to ¥2,235,154,094.49, a decrease from ¥2,370,644,737.61 in the previous period[18] - The total current assets are reported at 1,738,338,700.12 RMB, a decrease from 1,816,197,553.88 RMB, indicating a decline of about 4.3%[16] - The total non-current assets amount to 2,210,063,020.98 RMB, down from 2,257,988,401.13 RMB, representing a decrease of approximately 2.1%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 93,421[11] - Harbin Yuheng Group Co., Ltd. holds 32.13% of shares, totaling 706,248,522 shares, which are frozen[11] - The top ten shareholders include YU HENG INTERNATIONAL INVESTMENTS CORPORATION with 2.58% and ORIENTAL KEYSTONE INVESTMENT LIMITED with 1.95%[11][12] - The company has no controlling shareholder or actual controller as of the report date, following the bankruptcy of Harbin Yuheng Group[13] - The company’s stock held by Harbin Yuheng Group has been completely auctioned and transferred, with no remaining shares held by the group[13] Operational Efficiency - The total operating costs for the current period are ¥636,373,987.48, down 13.27% from ¥733,867,370.83 in the previous period[20] - Research and development expenses for the current period are ¥13,997,253.96, down from ¥19,378,770.25 in the previous period, indicating a reduction of 27.56%[20] - Cash paid for purchasing goods and services was ¥98,639,590.05, compared to ¥161,161,410.50 in the previous period, reflecting a decrease in operational expenditures[24] - Cash paid for employee compensation was ¥115,102,392.56, down from ¥160,976,169.26, indicating cost control measures[24] Investment Performance - The company reported an investment loss of ¥20,774,804.75, compared to a loss of ¥10,283,242.28 in the previous period, representing an increase in losses[20] - Investment income showed a significant decline of 102.03%, with losses from equity method investments increasing[9] - The company reported cash received from investment recoveries of ¥56,383,625.67, a significant drop from ¥300,150,000.00 in the previous period[24] Legal Matters - The company has ongoing litigation related to a contract dispute, with a total of 1,524.40 million RMB received and 140.09 million RMB still owed[14] Management and Control - The company’s management team remains stable, and its independent operational capability is not affected by the change in control[13]

证券代码：002437 证券简称：誉衡药业 哈尔滨誉衡药业股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | --- | --- | |------------------------------|--------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------| | | | | | | | √ | 特定对象调研 □分析师会议 | | | 投资者关系活 | □ | 媒体采访 □业绩说明会 | | ...